TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Recruiting now · Not applicable
Conditions studied: Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
In brief
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
Key facts
- Study ID
- NCT06487663
- Run by
- Tianjin Medical University Cancer Institute and Hospital
- People needed
- 40
- Starts
- 2020-10-27
- Expected to finish
- 2026-10-27
- Last updated by the study team
- 2024-07-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
- Sign informed consent
- When screening for age, the age should be ≥ 18 years old
- Eligible for TACE treatment
- ECOG physical condition score is 0 or 1
- No prior systemic therapy for HCC, especially immunotherapy
- According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation
You may not qualify if…
- Have any history of kidney disease or nephrotic syndrome
- Evidence of extrahepatic spread (EHS)
- Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control
- Any condition representing a contraindication to TACE as determined by the investigators
- Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding
- Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment)
- Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization)
- Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.
Where it is running
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.